Connect with us

Business News

Reinvent Technology Partners Announces Pricing of $600 Million Initial Public Offering

Published

on

AON Splash Image
ADVERTISEMENT


NEW YORK–()–Reinvent Technology Partners (the “Company”) announced today that it priced its initial public offering of 60,000,000 units at $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “RTP.U” beginning September 17, 2020. Each unit consists of one Class A ordinary share and one-fourth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on the NYSE under the…



Click here to view the original article.

Business News

Kemper Prices $400 Million Senior Notes Offering

Published

on

ADVERTISEMENT


CHICAGO–()–Kemper Corporation (NYSE: KMPR) announced today that it has priced a registered offering of $400 million of 2.400% senior notes due 2030. Kemper intends to use the net proceeds from this offering for general corporate purposes, which may include ordinary course working capital and investments in other business opportunities, including acquisitions, and to pay related fees and expenses.

Kemper anticipates that the offering will close on September 29, 2020, subject to the satisfaction of customary closing conditions.

BofA Securities, Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the transaction.

The offering is…



Click here to view the original article.

Continue Reading

Business News

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

Published

on

AON Splash Image
ADVERTISEMENT


BENSALEM, Pa.–()–Law Offices of Howard G. Smith announces an investigation on behalf of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) investors concerning the Company’s possible violations of federal securities laws.

On January 13, 2020, NextCure disclosed that Eli Lilly and Company had ended its collaboration agreement for the research and development of the Company’s leading product candidate, NC318, a first-in-class immunomedicine targeting the Siglec-15 immunomodulatory receptor particularly for patients with advanced or metastatic solid tumors.

On this news, the Company’s share price fell $4.70, or 8%, to close at $52.00 per share on January 13, 2020, thereby injuring…



Click here to view the original article.

Continue Reading

Business News

Penobscot Investment Management Promotes Colleen MacPherson, CFA to Director of Research

Published

on

AON Splash Image
ADVERTISEMENT


BOSTON–()–Penobscot Investment Management is proud to announce that Colleen MacPherson, CFA has been promoted to Director of Research. In MacPherson’s new role, she will oversee the firm’s research efforts to identify opportunities in equities, fixed income and other asset classes, while continuing to service clients as Portfolio Manager.

“Colleen has been an integral part of our investment committee since joining Penobscot. She is a skilled analyst and has made valuable contributions to every aspect of our research process,” said Dan Ford, President of Penobscot. “We are fortunate to have someone so capable to lead our research efforts.”

Prior to her tenure at Penobscot Investment Management, she…



Click here to view the original article.

Continue Reading

Trending

You might also like ...

Indee Labs Awarded Contract from the National Cancer Institute
AON Splash Image
National Storage Affiliates Trust Launches Public Offering of Common Shares
New Research Shows Two-Thirds of Organizations are Failing to Deliver Business Impact from Analytics Investments